Cd24 is a prognostic marker for multiple myeloma progression and survival

HIGHLIGHTS

• who: Noa Gross Even-Zohar and colleagues from the Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem have published the paper: CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival, in the Journal: (JOURNAL) of 18/05/2022
• what: This study evaluated the prognostic significance of CD24 expression on PCs in newly diagnosed patients treated uniformly with first-line bortezomib-based therapy. This study focused on the role of CD24 as a prognostic MFC marker at diagnosis. This study has several limitations of note.
• how: The . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.